Write what you believe about your stocks; every morning the cited record grades it: supported, challenged, or untouched. Never opinions.

Development · 13 Nov 2026

ALKEM, full dossier

Alkem Laboratories expects its US business to remain subdued in the near term, clocking around mid single-digit territory in topline for the full year FY27 due to pending remediations of its Daman facility and slower scale-up of its CDMO business.

1 publisher has reported this development. Each act of reporting is below, cited.

The record

Alkem Laboratories expects its US business to remain subdued in the near term, clocking around mid single-digit territory in topline for the full year FY27 due to pending remediations of its Daman facility and slower scale-up of its CDMO business.

indiatimes.com13 Nov 2026

Alkem Laboratories expects its US business to remain subdued in the near term, clocking around mid single-digit territory in topline for the full year FY27.

indiatimes.com13 Nov 2026

New here? The reader's guide explains every page, plate by plate.

fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.